CD Antigen Cancer Therapy Market

The global CD Antigen Cancer Therapy Market is valued at USD 26.6 Billion in 2023 and is projected to reach a value of USD 45.29 Billion by 2032 at a CAGR (Compound Annual Growth Rate) of 6.1% between 2024 and 2032.

Key highlights of CD Antigen Cancer Therapy Market

• The North American region dominated the market in 2023, obtaining the largest revenue share of 42.5%,
• The Asia Pacific region will witness remarkable growth with a CAGR during the forecast period,
• In 2023, the CD19 segment dominated the CD Antigen Cancer Therapy market with significant market share,
• The Monoclonal Antibodies (mAbs) segment dominated the market with 41.2% market share in 2023,
• The heightened awareness about cancer and the growing availability of advanced treatment options, which have collectively led to an increased demand for innovative therapies drives the CD Antigen Cancer Therapy market.

CD Antigen Cancer Therapy Market: Regional Overview

North America Dominated Sales with a 42.5% share in 2023. North America’s dominance in CD Antigen Cancer Therapy market is driven by robust healthcare infrastructure, coupled with high adoption rates of advanced medical technologies, and substantial investments in cancer R&D and the adoption of cancer therapy and the significant burden of cancer cases, particularly in the United States and Canada. For instance, data released by the Canadian Cancer Society in November 2023 revealed that approximately 239,100 individuals in Canada were diagnosed with cancer in 2023 alone. Also, it is projected that an estimated 2 out of 5 Canadians will develop cancer at some point during their lifetime. This high prevalence highlights the urgent need for efficient remedy processes to the lead in tackling the problems caused by cancer.

The region advantages from favorable reimbursement policies and a supportive regulatory environment, facilitating the swift adoption and commercialization of CD antigen cancer treatments. This favorable environment stimulates market expansion and motivates pharmaceutical companies to invest in cutting edge therapies. similarly using market expansion is the high prevalence of most cancers cases in North America, specially in the USA and Canada, which highlights the crucial need for efficient remedy solutions.

Key players' concentrated presence, coupled with strategic initiatives such as product approvals and increased investment in research and development activities, further augments North America's influence in the CD Antigen Cancer Therapy market. For instance, collaborations like the global strategic alliance between Kite, a subsidiary of Gilead, and Arcellx, Inc. to co-develop and commercialize CART-ddBCMA, highlight the region's commitment to advancing cancer treatment. The essential role that North America plays in propelling innovation and therapeutic improvements in cancer care is further evidenced by recent approvals, such as the approval of AstraZeneca's Imjudo for the treatment of Stage IV non-small cell lung cancer.

CD Antigen Cancer Therapy Market: Therapy Type Overview

The Monoclonal Antibodies (mAbs) segment dominated the CD Antigen Cancer Therapy market with the largest share of 41.2% in 2023. The CD Antigen Cancer Therapy market, segmented by the Therapy Type, is bifurcated into Monoclonal Antibodies (mAbs), Antibody-Drug Conjugates (ADCs), Chimeric Antigen Receptor (CAR) T-cell Therapy, Bi-specific T-cell Engagers (BiTEs), Radioimmunotherapy and Immunotoxins.

Monoclonal antibodies exhibit high specificity to cancer cells by binding to surface proteins and eliciting an immune response, positioning them as potent tools in cancer treatment. Given the escalating global cancer incidence, cancer monoclonal antibodies are poised to claim a significant market share in the CD Antigen Cancer Therapy market. For instance, according to the World Health Organization's February 2022 update, cancer-related fatalities reached approximately 10 million worldwide in 2020, with breast, lung, colon, rectum, prostate, skin (non-melanoma), and stomach cancers among the most prevalent.

The robust investments by global pharmaceutical entities in the research and development of cancer biologics, particularly monoclonal antibodies, reflect their efficacy and low toxicity profile compared to conventional chemotherapy. Approval procedures for new cancer monoclonal antibodies contribute to the market's expansion. For instance, the conditional approval of trastuzumab deruxtecan in the European Union for HER2-positive breast cancer treatment in January 2023 exemplifies regulatory responsiveness to innovative therapies.

Monoclonal antibodies have transformed cancer treatment offering precise therapy with minimized systemic toxicity engineered to target specific CD antigens on cancer cells. They are vital tools against a range of cancers because of their capacity to specifically target cancer cells and to stimulate the immune system to destroy them. This puts them at the forefront of the therapeutic arsenal.

The versatility of monoclonal antibodies in CD antigen cancer therapy is evident in their efficacy across a gamut of cancer types, from hematological to solid tumors. Their utility across a wide range of oncological contexts, including lymphoma, leukemia, breast, lung, and colorectal malignancies, confirms their position as the cornerstone of CD antigen-targeted therapeutics.

CD Antigen Cancer Therapy Market: Government Initiatives

• Vietnam's Ministry of Health initiated a patient support program in July 2023 with the goal of lowering the cost of the medicine used in targeted therapy, benetuximab vedotin, and enhancing the quality of life for individuals suffering from malignant lymphoma.
• The Department of Atomic Energy, in conjunction with the Tata Memorial Centre, a grant-in-aid institution, is spearheading the National Cancer Grid (NCG) initiative, which aims to establish a nationwide network of cancer centers, research institutes, patient groups, and charitable institutions. The program's objectives are to provide specialist oncology education and training, establish unified standards of patient care for cancer prevention, diagnosis, and treatment, and support cooperative fundamental, translational, and clinical cancer research. Currently, NCG's network spans over 270 hospitals in India.
• The India-UK Cancer Research Initiative would bring together top Indian and UK professionals in clinical research, demography research, new technologies, and physical sciences to develop a core set of research problems addressing concerns of affordability, prevention, and cancer care.
• The Global Breast Cancer Initiative (GBCI) of the World Health Organization was founded in 2021 and unites global and sectoral partners with the common objective of lowering breast cancer by 2.5% year, which would save 2.5 million lives over a 20-year period.
• The long-awaited National Cancer Plan, a road map and call to action to enhance all aspect of cancer care from prevention, screening, and early detection to treatment and survivorship care, was unveiled by the US National Cancer Institute on April 3, 2023.

Key Trends

• The shift towards personalized medicine driving tailored therapies treatments customized to each patient's unique biological characteristics is a significant trend for CD Antigen Cancer Therapy market. Healthcare professionals can choose the most appropriate course of treatment, such as CAR-T cell therapy, which specifically targets certain antigens, by examining the patterns of expression of particular CD antigens on a patient's cancer cells. Because it targets the molecular characteristics of the patient's cancer directly, this strategy maximizes therapy success while minimizing side effects.
• There is a growing trend towards exploration of novel CD antigens beyond CD19 and CD20 expanding therapeutic options. Traditionally, CD19 and CD20 have been the primary targets for CAR-T cell therapies. Researchers can design therapeutics for tumors that might not respond adequately to CD19-targeted treatments by focusing on novel antigens like CD22 or CD30.
• There is a growing trend towards advancements in gene editing technologies like CRISPR facilitating next-generation CAR-T therapies. Immunotherapy has undergone a revolutionary change because of gene editing technologies like CRISPR, which allow for precise adjustments to immune cells' genetic makeup. Researchers can use CRISPR to boost CAR-T cell performance, increase the cells' endurance within the body, and overcome obstacles like cancer cells' ability to evade the immune system. These developments open the door to next-generation CAR-T therapies that have improved potency, safety, and longevity, advancing our quest for more efficient cancer treatments.

Premium Insights

The CD Antigen Cancer Therapy market is driven by the escalating global cancer prevalence, pivotal R&D efforts from key industry players, and the escalating demand for personalized medicine and the expansion of patient assistance programs (PAPs), government initiatives aimed at raising cancer awareness. For instance, in November 2023, the American Cancer Society launched the Community Access to Resources, Education, and Support (ACS CARES) program, leveraging a mobile application to offer cancer patients quality information and personalized support. Initiatives like ACS CARES are positioned to support the adoption of cancer therapy and spur market growth by improving the accessibility of cancer care services to patients and caregivers through increased information distribution.

The mounting global cancer burden underscores the imperative for diverse cancer therapies, thereby fueling market growth. For instance, as of January 2024, the American Cancer Society reported over 18 million Americans with a history of cancer in 2022, with projections indicating over 2 million new cancer cases expected to be diagnosed in the United States in 2024 alone. The increased prevalence of cancer highlights the urgent need for efficient treatment measures, which in turn fuels the market's growth and creates a demand for novel CD antigen cancer treatments.

Technological advancements geared towards enhancing personalized medicine planning are driving demand and adoption, further contributing to market expansion. Healthcare providers are empowered to plan treatments and do early multi-cancer diagnoses with the use of artificial intelligence (AI)-based personalized care technology. These technologies, which are used to create personalized medical goods using patient data, are intended to improve cancer patients' therapeutic efficacy and safety, which will increase demand for personalized medicine.

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

Increasing Awareness about Cancer and Available Treatment Options drives the CD Antigen Cancer Therapy market

Awareness campaigns, educational programs, and media coverage play pivotal roles in disseminating information about cancer and available treatment options to the general public. A better knowledge of the disease motivates people to prioritize cancer screenings and pursue early diagnosis, both of which are essential for successful treatment outcomes. Furthermore, people are better prepared to participate in clinical trials, have educated conversations with healthcare professionals, and investigate appropriate treatment alternatives when they get more understanding about various therapy methods, including CD antigen cancer therapies. This increased knowledge promotes early detection and a proactive approach to cancer management, which in turn increases demand for medicines that target CD antigens.

The development and implementation of novel CD antigen cancer therapies involve substantial financial investments at various stages of the product lifecycle restraints the market

Research and development activities, including preclinical studies and clinical trials, require significant funding to demonstrate the safety and efficacy of the therapy. The overall cost is further increased by setting up manufacturing facilities that adhere to Good Manufacturing Practices (GMP) guidelines. Moreover, there are additional costs associated with post-approval activities like marketing, distribution, and continuing regulatory compliance. Therapy affordability and accessibility are hampered by these high development and implementation costs, especially for patients living in areas with poor financial resources or insufficient insurance coverage.

The regulatory landscape for CD antigen cancer therapies involves overcoming numerous challenges related to compliance with regulatory requirements, submission of comprehensive clinical data, and coordination with regulatory agencies

Regulatory approval processes are often complex, time-consuming, and resource-intensive, requiring meticulous planning and execution. Timelines for market introduction, development, and cost can all be greatly impacted by delays or difficulties in securing regulatory permission. Moreover, the regulatory complexity is increased by the need for customized regulatory strategies for every jurisdiction due to variations in regulatory needs throughout nations and regions. Overcoming these regulatory challenges requires close collaboration between industry stakeholders and regulatory authorities to ensure compliance with applicable regulations and expedite market access for innovative CD antigen cancer therapies.

Competitive Landscape

The competitive landscape of the CD Antigen Cancer Therapy market is characterized by a dynamic interplay of pharmaceutical giants, emerging biotech firms, and academic institutions pioneering innovative treatments. Established players like Bristol Myers Squibb, Novartis, and Roche maintain dominance with their extensive pipelines and commercialization capabilities, particularly in CAR-T cell therapies targeting CD19 and CD22 antigens. However, smaller biotechs such as Kite Pharma and Juno Therapeutics, now subsidiaries of Gilead and Bristol Myers Squibb respectively, have demonstrated agility in developing novel CD antigen-targeted therapies, expanding the market's scope.

The key players in the global CD Antigen Cancer Therapy market include - Merck & Co. Inc. (U.S.), Johnson & Johnson Inc. (U.S.), Amgen Inc. (U.S.), AbbVie Inc. (U.S.), Novartis AG (Switzerland), Roche Holdings AG (Switzerland), Bristol Myers Squibb Company (U.S.), Biogen Inc. (U.S.), Celgene Corp. (U.S.), Genmab A/S (Denmark), Immunomedics Inc. (U.S.), Gilead Sciences Inc. (U.S.), AstraZeneca PLC (UK), Takeda Pharmaceutical Company Ltd. (Japan), Seattle Genetics Inc. (U.S.) among others.

Recent Market Developments

• In 2024, Amgen has announced that the U.S. Food and Drug Administration (FDA) has granted approval for IMDELLTRA™ (tarlatamab-dlle) to treat adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression following platinum-based chemotherapy.
• In 2022, Results from a pooled exploratory analysis of the MONALEESA Phase III study were released by Novartis, confirming an extra benefit of over a year in overall survival (OS) for a subset of patients with advanced, aggressive, hormone receptor-positive, HER2-negative breast cancer. These findings highlight the potential value of MONALEESA treatments in enhancing patient outcomes.
• In 2023, The SNAP-CAR T-cell platform was unveiled by Coeptis Therapeutics Holdings, Inc. and exhibits potential in targeting several cancer antigens, including as CD20 and HER2. This is a big improvement since it uses different adaptors, which may lead to tailored therapy techniques for cancer therapies that are more effective.
• In May 2023, EPKINLY (epcoritamab-bysp), a T-cell engaging bispecific antibody developed by Genmab A/S, was approved by the USFDA to treat adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
• In April 2023, The USFDA approved Genentech, a Roche Group company, for use of Polivy (polatuzumab vedotin-piiq) in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin, and prednisone (R-CHP) as a cancer therapy medication. The medication is used to treat adult patients with diffuse large B-cell lymphoma (DLBCL) who have not had prior treatment.
• In April 2023, Omisirge (omidubicel-onlv), an allogeneic cell treatment developed by Gamida Cell Ltd, was approved by the USFDA for use in treating hematologic malignancies in adults and children patients aged 12 years and above.

The global CD Antigen Cancer Therapy market can be categorized as Type of CD Antigen Targeted, Therapy Type, Cancer Type, End User, and Region.